Pharmaceutical Preparations · DE · CIK 1609809
Develops microbiome-based therapies to prevent and treat bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases
Comparable business profile · signals at a glance
Coverage (30d): 1 reputable article.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
In the 90 days to Feb 15, 2026: 4 sold $4K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 15, 2026 | Shaff Eric D.Director | Sell | 259 | $8.47 | $2K |
| Feb 15, 2026 | Henn Matthew RSee Remarks | Sell | 89 | $8.47 | $754 |
| Feb 15, 2026 | Desrosier ThomasSee Remarks | Sell | 78 | $8.47 | $661 |
| Feb 15, 2026 | Young Teresa L.See Remarks | Sell | 75 | $8.47 | $635 |
| Nov 15, 2025 | Henn Matthew RSee Remarks | Sell | 1,257 | $17.30 | $22K |
| Nov 15, 2025 | Young Teresa L.See Remarks | Sell | 1,042 | $17.30 | $18K |
| Nov 15, 2025 | Shaff Eric D.Director | Sell | 217 | $17.30 | $4K |
| Nov 15, 2025 | Desrosier ThomasSee Remarks | Sell | 76 | $17.30 | $1K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.